Anti-TPO IgG ELISA Kit

Catalog No. ABIN1326902

This Colorimetric ELISA kit is designed for the quantitative measurement of Human Anti-TPO IgG.

Quick Overview for Anti-TPO IgG ELISA Kit (ABIN1326902)

Target: Anti-TPO IgG (TPO IgG) (Anti-Thyroid Peroxidase IgG (TPO IgG))

Reactivity: Human

Detection Method: Colorimetric

Method Type: Competition ELISA

Application: ELISA

Sample Type: Serum

Product Details Anti-TPO IgG ELISA Kit

Purpose: Diluted patient serum is added to wells coated with purified TPO recombinant antigen. TPO IgG specific antibody, if present, binds to the antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color generated is proportional to the amount of IgG specific antibody in the sample.

Analytical Method: Qualitative

Application Details

Plate: Pre-coated

Restrictions: For Research Use only

Handling

Storage: 4 °C

Target Details for Anti-TPO IgG

Target: Anti-TPO IgG (TPO IgG) (Anti-Thyroid Peroxidase IgG (TPO IgG))

Alternative Name: Thyroid Peroxidase (TPO) IgG

Target Type: Antibody, Antibody

Background: Thyroid peroxidase (TPO), is the major autoantigen (933 amino acid residue) in the thyroid microsomal antigen (TMA) particle. The purification and preparation of this antigenhas made testing for TMA antibodies obsolete. Assays for TPO antibodies include ELISA, precipitation of radiolabeled TPO-bound autoantibodies with protein A, competition for TPO binding to immobilized anti-TPO murine monoclonal antibodies, autoantibody capture by TPO-coated beads and chemiluminescence. All tests correlate well with detection of TMA. ELISA using TPO recombinant antigen is the most popular assay.Detection of TPO antibodies is strong evidence against a goiter or non-autoimmune causes of hypothyroidism. The annual risk for the development of hypothyroidism is 3% to 4% per year if TPO antibodies are present and TSH is elevated.TPO antibodies are present in 8-9% normal controls, 57-74% patients with Graves disease, 99-100% of Hashimoto disease or idiopathic myxedema, 19% with differentiated thyroid cancer, no patients with subacute thyroiditis and 11% of those with other miscellaneous non-autoimmune thyroid diseases. The prevalence of positive TPO antibodies is higher in elderly (mean age 80 years) women (10%) compared to elderly men (2%).Autoantibody concentration in centenarians also decreases.Studies of TPO epitopes in each domain, A and B, and detection of their specific autoantibodies suggest that the epitope-specific TPO antibodies ratio (AB) does not change over time in inidual patients and that TPO epitope autoantibody patterns may be inherited.